AGA Family of Websites: Gastro.org
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board
July 31, 2019

United Healthcare: Medical benefit coverage changes for preferred infliximab products

United Healthcare Commercial (UHC) has changed its drug policy for infliximab products used to treat Crohn’s disease and ulcerative colitis.

Share on facebook
Share on twitter
Share on linkedin
Share on email

Effective Oct. 1, 2019, UHC will no longer require the use of Remicade prior to coverage for Inflectra. As part of the notification/prior authorization review, UHC will require documentation to support the clinical requirement that members must try both Inflectra and Remicade, experience an adverse reaction, or have a contradiction to Inflectra and Remicade to receive coverage approval for Renflexis. 


Notification/prior authorization for Remicade is required when administered in an outpatient hospital setting. Notification/prior authorization for Inflectra is required when administered in an outpatient hospital, office or home setting.


See the July 2019 United Network Bulletin for more information. 

Discussion Icon

Discuss this news

Share this article in the AGA Community, your member-only platform for sharing your thoughts and ideas with your colleagues.

Not a member? Join AGA.

By using this site, you agree to our updated Privacy Policy.